Eli Lilly and Company
Eli Lilly Reports Q3 2024 Financial Results with Strong Revenue Growth
Summary
Eli Lilly and Company reported Q3 2024 financial results highlighting a 20% increase in total revenue to $11.44 billion, driven by volume growth from new products Mounjaro and Zepbound. Non-incretin revenue increased by 17%, while earnings per share (EPS) on a reported basis were $1.07 and $1.18 on a non-GAAP basis, both including $3.08 of acquired IPR&D charges. The company updated its 2024 revenue guidance to $45.4 to $46.0 billion and adjusted EPS guidance to $12.05 to $12.55 on a reported basis and $13.02 to $13.52 on a non-GAAP basis.
Profitelligence Alerts
Get alerts for LLY
Be first to know when Eli Lilly and Company files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Eli Lilly and Company
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.
Official SEC Documents
Advertisement